Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 9/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | TPO | P07202 | 8/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259212 | 0.83 | MPO (0.62) | MPOOPRM1TPOCYP3A4 | |
| SCHEMBL34461789 | 0.81 | PNP (0.53) | MPOTPOMCL1KMT2A | |
| SCHEMBL34461750 | 0.70 | ADORA2A (0.38) | MPOOPRM1MCL1ALDH1A1BRD4 | |
| SCHEMBL34461757 | 0.69 | ADORA2A (0.62) | MCL1ALDH1A1 | |
| SCHEMBL14761683 | 0.62 | CYP1A2 (0.40) | MCL1ALDH1A1LTA4HCYP3A4MEN1 | |
| SCHEMBL21667353 | 0.61 | SMN1; SMN2 (0.47) | ALDH1A1MEN1KMT2A | |
| SCHEMBL8242667 | 0.61 | POLB (0.45) | MCL1ALDH1A1MEN1KMT2A | |
| SCHEMBL9394061 | 0.61 | ALDH1A1 (0.51) | ALDH1A1BRD4CYP3A4NSD2ABL1 | |
| SCHEMBL3521372 | 0.60 | NPC1 (0.53) | ALDH1A1PKMLTA4HMEN1KMT2A | |
| SCHEMBL25035706 | 0.59 | PKM (0.56) | ALDH1A1PKMLTA4HMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | MPO 3248/4885OPRM1 2999/4885TPO 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.